Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSanford Health Plan step therapy Coverage Update |…
    Ask Trek AI about this page
    Currentsanford health planPolicy N/A

    Step Therapy Criteria for Select Pharmacy & Specialty Drugs

    Customize your policy alerts

    Sign up for all sanford health plan policy alerts

    Know when sanford health plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Step therapy requirements for select pharmacy and specialty drugs for Sanford Health Plan, listing prerequisite trials required before coverage of specified products. Affects prescribers and prior authorization reviewers for Sanford Health Plan members.

    Policy Summary
    Payersanford health plan
    PolicyStep Therapy Criteria for Select Pharmacy & Specialty Drugs
    Policy CodePolicy N/A
    Change TypeMinor / no material changes
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionDocument and provide evidence of the specified prior trial(s) (e.g., trial of topical fluorouracil or imiquimod for diclofenac gel) when requesting authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9distinct product sections listed in this part of the document
    1required prior-step for Diclofenac GEL
    2generic trials required for antidepressants
    2products explicitly shown in excerpt

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1products with explicit step requirement
    partialdocument segment

    Coverage / Step Therapy Criteria

    Initial Therapy - Diclofenac Sodium GEL 3%

    Covered when ALL of the following prior trials are met for Diclofenac Sodium GEL 3%:

    Diclofenac (actinic keratosis) prerequisite: Trial of either topical fluorouracil OR topical imiquimod1 trial

    From 'Details' section for Diclofenac

    Initial Therapy - Antidepressants

    Covered when ALL of the following are met for listed antidepressant branded products:

    Antidepressant step: Trial of two generic formulary antidepressants from the listed agents OR approve for continuation of prior therapy2 trials

    Agents listed in Details: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride

    Initial Therapy - Atypical Antipsychotics

    Covered when ALL of the following are met for listed atypical antipsychotics:

    Atypical antipsychotic step: Trial of two oral generic formulary atypical antipsychotics from the listed agents OR approve for continuation of prior therapy2 trials

    Agents listed in Details: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone

    Initial Therapy - Invega Hafyera

    Covered when the following are met for Invega Hafyera:

    Invega Hafyera step: For new starts, trial of Invega Sustenna OR Invega Trinza; continuation of prior therapy is approved1 trial

    Step applies to new starts only

    Initial Therapy - Relistor

    Covered when the following are met for Relistor:

    Relistor step: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, OR Movantik1 trial

    From Details section

    Initial Therapy - Rytary

    Covered when the following are met for Rytary:

    Rytary step: Trial of one generic carbidopa/levodopa containing formulation1 trial

    From Details section

    Initial therapy step criteria

    Covered when the following step requirement is met for initial starts:

    Rytary initial: Trial of one generic carbidopa/levodopa containing formulation is requiredtrial documented

    from chunk 19

    Zonisade initial: Trial of generic zonisamide capsule is required for new startstrial documented

    Zonisade step applies to new starts only; continuation approved for prior therapy (chunk 22)

    For Invega Hafyera, the step therapy requirement applies only to new starts. For initial therapy requests, the member must have a documented trial of Invega Sustenna OR Invega Trinza before Invega Hafyera will be approved. Continuation of prior therapy with Invega Hafyera is allowed (existing users do not need to re‑complete the step).

    For Zonisade (generic zonisamide capsule), the step requirement is limited to new starts. A documented trial of a generic zonisamide capsule is required for initial approval. Continuation of prior Zonisade therapy is approved and the step does not apply to members already receiving the medication.

    Provider Actions, Documentation & Denial Risk

    Prior Authorization

    Actinic keratosis — prior topical therapy required

    Diclofenac Sodium GEL 3% requires a prior trial of either topical fluorouracil or topical imiquimod before authorization. Document the trial of one of these topical therapies when submitting an initial prior authorization request.

    • Required trial: topical fluorouracil OR topical imiquimod
    • Applies to initial starts for Diclofenac Sodium GEL 3%
    Prior Authorization

    Antidepressant — two generic trials required (or continuation)

    Branded antidepressants listed (e.g., Emsam, Exxua) require documentation of trials of two generic formulary antidepressants from the specified list, or the request must be for continuation of prior therapy. Include dates, agents, and treatment outcomes for each generic trial in the prior authorization submission.

    • Required trials: two generic formulary antidepressants (agents listed in policy: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine HCl)

    Initial Therapy - Required Prior Trials

    Diclofenac initial therapy

    Initial therapy prerequisite for Diclofenac Sodium GEL 3% (actinic keratosis):

    Diclofenac initial step: Trial of topical fluorouracil OR topical imiquimod1 trial

    From Details

    Relistor initial therapy

    Initial therapy prerequisite for Relistor:

    Relistor initial step: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, OR Movantik1 trial

    From Details

    Step Trial Requirements (Summary Table)

    ProductStep requirement
    Diclofenac Sodium GEL 3%
    Trial of either topical fluorouracil OR topical imiquimod documented
    Product(s)Step requirement
    Emsam; Exxua; Exxua Titration Pack; Fetzima; Fetzima Titration Pack
    Trial of two generic formulary antidepressants from the listed agents (bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine HCl) OR approval for continuation of prior therapy
    Product(s)Step requirement
    Fanapt; Fanapt Titration Pack A; Lybalvi; Secuado
    Trial of two oral generic formulary atypical antipsychotics from the listed agents (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) OR approval for continuation of prior therapy
    ProductStep requirement / Notes
    Invega Hafyera
    For new starts, trial of Invega Sustenna OR Invega Trinza required; step applies to new starts only — continuation of prior Invega Hafyera therapy is approved
    ProductStep requirement
    Relistor
    Trial of one of the following: lubiprostone, Constulose, Enulose, Generlac, lactulose, OR Movantik documented
    ProductStep requirement
    Rytary
    Trial of one generic carbidopa/levodopa–containing formulation documented prior to approval
    ScopeSummary of step requirement
    Initial starts for branded products listed in this policy
    Trial of the specified generic formulation is required before coverage of the branded product for new starts (examples: trial of one generic carbidopa/levodopa before Rytary; trial of generic zonisamide capsule before Zonisade). Note: certain steps (e.g., Invega Hafyera, Zonisade) are waived for continuation of prior therapy

    Continuation of Therapy / Existing Users

    Antidepressant continuation

    Continuation of prior therapy is explicitly allowed for certain antidepressant branded products.

    Antidepressant continuation: Approve for continuation of prior therapyN/A

    Stated in Details

    Atypical antipsychotic / Invega continuation

    Continuation of prior therapy is allowed for listed atypical antipsychotics and Invega Hafyera.

    Atypical antipsychotic continuation: Approve for continuation of prior therapyN/A

    Stated in Details

    Policy Summary
    Payersanford health plan
    PolicyStep Therapy Criteria for Select Pharmacy & Specialty Drugs
    Policy CodePolicy N/A
    Change TypeMinor / no material changes
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionDocument and provide evidence of the specified prior trial(s) (e.g., trial of topical fluorouracil or imiquimod for diclofenac gel) when requesting authorization.
    SourceLink
    On This Page
    Coverage / Step Therapy CriteriaProvider Actions, Documentation & Denial RiskInitial Therapy - Required Prior TrialsStep Trial Requirements (Summary Table)Continuation of Therapy / Existing Users
  1. Continuation requests: approve for continuation of prior therapy
  2. Prior Authorization

    Atypical antipsychotic — two generic trials required (or continuation)

    Listed atypical antipsychotics require a trial of two oral generic formulary atypical antipsychotics (agents enumerated in the policy) prior to approval for new therapy; continuation of prior therapy is allowed. Provide documentation of the two generic agent trials when requesting initial approval.

    • Required trials: two oral generic atypical antipsychotics (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)
    • Continuation requests: approve for continuation of prior therapy
    Prior Authorization

    Invega Hafyera — Sustenna/Trinza trial required for new starts

    For new starts of Invega Hafyera, a trial of Invega Sustenna or Invega Trinza is required before Invega Hafyera will be approved; members already receiving therapy may be approved for continuation. Include documentation of the prior Sustenna or Trinza trial for initial requests.

    • Required trial (new starts): Invega Sustenna OR Invega Trinza
    • Step applies to new starts only; continuation of prior Hafyera therapy is approved
    Prior Authorization

    Relistor — trial of listed laxatives required

    Relistor requires a prior trial of alternative constipation agents (examples listed in the policy) before authorization. Submit documentation of a trial of one of the listed agents when requesting initial coverage for Relistor.

    • Required trial options: lubiprostone, Constulose, Enulose, Generlac, lactulose, OR Movantik
    • Document agent, dates, and response/failure
    Prior Authorization

    Rytary — generic carbidopa/levodopa trial required

    Rytary requires a documented trial of one generic carbidopa/levodopa containing formulation prior to approval for initial therapy. Provide specific documentation of the generic formulation trial in the prior authorization request.

    • Required trial: one generic carbidopa/levodopa formulation
    • Document agent name, dates, and reason for switching if applicable
    Prior Authorization

    Prior authorization — required evidence of prior trials for initial starts

    Prior authorization for initial starts requires evidence of the specified prior trial(s) described in the policy; continuation requests for members already on therapy (where noted, e.g., Zonisade, Invega Hafyera, certain antidepressants/antipsychotics) may be approved without repeating the step.

    • Initial approvals: submit documentation of required prior trial(s)
    • Continuation approvals: allowed for prior users where policy notes continuation is approved (e.g., Zonisade, Invega Hafyera, certain antidepressants/antipsychotics)
    Step Therapy

    Diclofenac (actinic keratosis) — step therapy requires topical fluorouracil or imiquimod

    Step therapy for Diclofenac Sodium GEL 3% requires a prior trial of topical fluorouracil or topical imiquimod before coverage will be granted. Ensure the prior trial is documented for initial authorization requests for diclofenac gel.

    • Step required: topical fluorouracil OR topical imiquimod
    • Applies prior to Diclofenac Sodium GEL 3% coverage
    Step Therapy

    Antidepressant — two generic formulary trials required as step

    For the listed branded antidepressants (Emsam, Exxua, etc.), step therapy requires trials of two generic formulary antidepressants from the policy’s specified list; continuation of prior therapy is permitted. Include documentation of both generic trials for initial requests.

    • Required step: two generic formulary antidepressants (see policy list)
    • Continuation: prior therapy may be approved without repeating step
    Step Therapy

    Atypical antipsychotic — two generic oral trials required

    Step therapy for the listed atypical antipsychotics requires trials of two oral generic formulary atypical antipsychotics prior to approval; continuation of prior therapy is allowed. Provide documentation of the two generic oral atypical antipsychotic trials for initial authorization.

    • Required step: two oral generic atypical antipsychotics (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)
    • Continuation: approve for members already on therapy
    Step Therapy

    Invega Hafyera — new-start step requires Sustenna or Trinza

    Invega Hafyera’s step requirement applies to new starts only and requires trial of Invega Sustenna or Invega Trinza; prior users may be approved for continuation. For initial requests, include documentation of the Sustenna or Trinza trial.

    • Step (new starts): Invega Sustenna OR Invega Trinza
    • Step waived for continuation of prior Hafyera therapy
    Step Therapy

    Relistor — step requires trial of listed laxatives

    Relistor step therapy requires trial of one of the listed alternative constipation agents (lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik) before authorization. Document the tried agent and response when requesting approval.

    • Required step options: lubiprostone; Constulose; Enulose; Generlac; lactulose; Movantik
    • Document treatment duration and outcome
    Step Therapy

    Rytary — step requires generic carbidopa/levodopa trial

    Rytary’s step therapy requires a trial of one generic carbidopa/levodopa containing formulation before initial approval. Include the generic formulation name and trial dates in the prior authorization documentation.

    • Required step: one generic carbidopa/levodopa formulation
    • Document product name, dates, and reason for inadequate response if applicable
    Step Therapy

    Step trial requirements — specified generic trials required for initial starts

    Step trial requirements across the policy consolidate that initial starts require documented trials of the specified generic formulations (for example, Rytary requires a generic carbidopa/levodopa trial; Zonisade requires a generic zonisamide capsule trial). For products where continuation is allowed, do not repeat the step for members already on therapy.

    • Examples: Rytary — trial of one generic carbidopa/levodopa; Zonisade — trial of generic zonisamide capsule (step applies to new starts only)
    • Continuation of prior therapy may be approved without repeating the step
    Documentation Required

    Actinic keratosis prior therapy documentation required

    For diclofenac gel, prior therapy documentation must show a trial of topical fluorouracil or topical imiquimod. Include agent name(s), dates, duration, and reason for failure or intolerance in the submission.

    • Documentation required: topical fluorouracil OR topical imiquimod trial
    • Include dates, duration, and outcome
    Documentation Required

    Antidepressant — trial documentation required

    For branded antidepressants, document trials of two generic formulary antidepressants (agents listed in the policy) or provide evidence of continuation of prior therapy. Include agent names, trial dates, durations, and treatment response.

    • Documentation required: two generic antidepressant trials OR evidence of continuation
    • Provide dates, durations, and reason for inadequate response or intolerance
    Documentation Required

    Atypical antipsychotic — trial documentation required

    For atypical antipsychotics, submit documentation of trials of two oral generic atypical antipsychotics or evidence of continuation of prior therapy. Include agent names, dates, durations, and clinical response.

    • Documentation required: two oral generic atypical antipsychotic trials OR continuation history
    • Include dates, duration, and reason for switching
    Documentation Required

    Required documentation — specific generic trial evidence

    For initial approvals that require a generic-formulation trial (e.g., Rytary, Zonisade), provide documentation of the specific generic trial used to meet the step requirement. Continuation requests for members already on therapy may be approved without repeating the step when the policy specifies.

    • Required documentation: evidence of prior trial of the specified generic formulation (e.g., generic carbidopa/levodopa for Rytary; generic zonisamide for Zonisade)
    • Continuation: prior users may be approved without repeating the step where noted
    Denial Risk

    Denial risk — actinic keratosis prerequisite topical therapy missing

    Failure to document a prior trial of topical fluorouracil or topical imiquimod for diclofenac gel may result in denial of the request. Ensure the required topical trial is clearly documented for initial diclofenac gel approvals.

    • Denial risk: no documented trial of topical fluorouracil or topical imiquimod for diclofenac gel
    Denial Risk

    Denial risk — antidepressant step trials absent

    For the listed branded antidepressants, absence of documented trials of two generic formulary antidepressants may trigger denial. Provide complete documentation of both generic trials or evidence of continuation to avoid non-approval.

    • Denial risk: lack of two documented generic antidepressant trials for initial branded antidepressant requests
    Denial Risk

    Denial risk — atypical antipsychotic step trials absent

    For listed atypical antipsychotics, failure to show trials of two oral generic formulary atypical antipsychotics may lead to denial. Ensure both generic agent trials are documented for initial approvals.

    • Denial risk: absence of two documented generic oral atypical antipsychotic trials
    Denial Risk

    Denial risk — Invega Hafyera new-start trial missing

    For new starts of Invega Hafyera, not documenting a prior trial of Invega Sustenna or Invega Trinza may result in non-approval. Provide evidence of the required Sustenna or Trinza trial for initial requests.

    • Denial risk: no documented trial of Invega Sustenna or Invega Trinza for new starts
    Denial Risk

    Denial risk — Relistor prior laxative trial missing

    For Relistor, absence of a trial of one of the listed laxatives (lubiprostone, lactulose, Movantik, etc.) may trigger denial. Document the prior laxative trial with dates and response when submitting the request.

    • Denial risk: no documented trial of listed alternative constipation agents
    Denial Risk

    Denial risk — Rytary generic trial missing

    For Rytary, failure to document a prior trial of a generic carbidopa/levodopa formulation may trigger denial of the initial request. Include the generic trial details in the prior authorization.

    • Denial risk: no documented trial of generic carbidopa/levodopa prior to Rytary
    Denial Risk

    Denial risk — missing step trial documentation

    Failure to document the required prior trial(s) with the specified generic formulations (for example, generic carbidopa/levodopa for Rytary or generic zonisamide capsule for Zonisade) may result in denial. Ensure all step trials required by the policy are supported with documentation in the request.

    • Denial risk: incomplete or missing documentation of required prior trials for initial starts
    • Include agent names, dates, durations, and clinical rationale for failure

    Rytary initial therapy

    Initial therapy prerequisite for Rytary:

    Rytary initial step: Trial of one generic carbidopa/levodopa formulation1 trial

    From Details

    Initial therapy

    Initial therapy step requirements for new starts

    Rytary initial: Require trial of one generic carbidopa/levodopa containing formulation before Rytarytrial documented

    chunk 19

    Zonisade initial: Require trial of generic zonisamide capsule before Zonisade for new startstrial documented

    chunk 22

    Continuation therapy

    Continuation rules for existing therapy

    Zonisade continuation: Approve continuation of prior Zonisade therapy without requiring the stepexisting therapy documented

    chunk 22